2182 results about "Powder diffraction" patented technology

A hydroprocessing bulk catalyst is provided. A process to prepare hydroprocessing bulk catalysts is also provided. The hydroprocessing catalyst has the formula (M^t)_d(L^u)_b(S^v)_d(C^w)_e(H^x)_f(O^y)_g(N^z)_h, wherein M is at least one group VIB metal; promoter metal L is optional and if present, L is at least one Group VIII non-noble metal; t, u, v, w, x, y, z representing the total charge for each of the components (M, L, S, C, H, O and N, respectively); ta+ub+vd+we+xf+yg+zh=0; 0 =<b; and 0=<b/a=<5, (a+0.5b)<=d<=(5a+2b), 0<=e<=11(a+b), 0<=f<=7(a+b), 0<=g<=5(a+b), 0<=h<=0.5(a+b). The catalyst has an X-ray powder diffraction pattern with at least one broad diffraction peak at any of Bragg angles: 8 to 18°, 32 to 40°, and 55 to 65° (from 0 to 70° 2-θ scale). In one embodiment, the catalyst is prepared by sulfiding at least one Group VIB metal compound and optionally at least one group VIII metal compound with a sulfiding agent forming a catalyst precursor; and mixing the catalyst precursor with a hydrocarbon compound to form the hydroprocessing catalyst composition.

The present invention relates to a test chamber that can be used to perform a variety of X-ray and neutron spectroscopy experiments including powder diffraction, small-angle scattering, X-ray absorption spectroscopy, and pair distribution functions, such chamber comprising a first electrode with an X-ray transparent window; a second electrode with an X-ray transparent window; a plurality of insulating gaskets providing a hermetic seal around the sample and preventing contact between said first and second electrodes; and an insulating housing into which the first electrode is secured.

A novel crystal form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate, and having favorable characteristics, is characterized by its x-ray powder diffraction pattern and/or by its infra-red spectrum.

The invention discloses an ambroxol hydrochloride crystal and a medicine composition prepared by the ambroxol hydrochloride crystal. The ambroxol hydrochloride crystal shows specific diffractive peaks in parts of 6.9 degrees, 7.2 degrees, 12.8 degrees, 15.6 degrees, 17.5 degrees, 20 degrees, 21 degrees, 22 degrees and 24 degrees in an X-ray powder diffraction pattern which is shown in form of 2 Theta +/-0.2 degrees. The prepared ambroxol hydrochloride crystal is high in yield and liquidity; and the amount of lubricant in original prescription is halved, so that the weight and uniformity of tablets can meet the specification.

The invention discloses a super-macroporous silicate molecular sieve material and a preparation method thereof, the molecular sieve has the X ray powder diffraction characteristic shown in Table 1, is obtained by hydrothermal synthesis method, has a three-dimensional pore structure of 18 * 12 * 10, good thermal stability, and larger specific surface area, can be incorporated into heteroatom, and has potential application values in petrochemistry, fine chemical engineering and life science and other fields.

The invention discloses a C crystal form of canagliflozin and a crystal preparation method of the canagliflozin. The X-ray powder of the canagliflozin, which is diffracted at diffraction angles 2 theta which are equal to 3.4 +/- 0.1, 6.5 +/- 0.1, 12.7 +/- 0.1, 15.8 +/- 0.1, 19.8 +/- 0.1, 24.3 +/- 0.1, 24.8 +/- 0.1 and 29.1 +/- 0.1, has characteristic peaks and is called as C crystal form canagliflozin. The method has the beneficial effects of being simple to operate and less in energy consumption. The prepared novel crystal form product is good in stability, large in solubility and rapid in dissolution rate; the purity of the novel crystal product is higher than 99% and the yield of the novel crystal product is 91% or so; the purity, the color and the shape of the novel crystal product are not changed after the novel crystal product is stored for 100 days at a normal temperature under a drying condition. The novel crystal product can be easily smashed and is easily compatible with the dosage forms of medicine compositions as well as is low in cost. Thus, the novel crystal product is easily suitable for large-scale commercial and industrial applications.

The invention discloses a canagliflozin of crystal form A, and a crystallization preparation method thereof. The X-ray powder diffraction pattern of the canagliflozin of crystal form A has characteristic peaks at diffraction angles 2theta with the values of 3.7+/-0.1, 3.9+/-0.1, 7.7+/-0.1, 7.9+/-0.1, 11.5+/-0.1, 13.1+/-0.1, 13.5+/-0.1, 14.3+/-0.1, 15.5+/-0.1, 17.3+/-0.1, 18.8+/-0.1, 19.3+/-0.1, 20.3+/-0.1, 22.5+/-0.1, 22.7+/-0.1, 23.2+/-0.1 and 23.4+/-0.1. The preparation method has the advantages of simplicity and easy operation of operation steps, short time and less energy consumption. The above product prepared in the invention has a good stability, high a purity of above 99%, and has a yield of about 90%, and the purity, the color and the form of the product are unchanged after the product is stored under normal temperature dry conditions for 100d.

The invention relates to a lansoprazole crystalline compound. An X-ray powder diffraction pattern represented by a diffraction angle of 2 theta +/- 0.2 DEG displays feature diffraction peaks at the positions of 5.8 DEG, 7.5 DEG, 9.1 DEG, 11.8 DEG, 12.1 DEG, 12.8 DEG, 13.3 DEG, 15.6 DEG, 16.7 DEG, 18.3 DEG, 20.4 DEG, 25.7 DEG, 26.8 DEG and 31.5 DEG. The invention also relates to a lansoprazole enteric capsule containing the lansoprazole crystalline compound. The lansoprazole enteric capsule comprises 20 to 60 parts of l crystalline compound, 90 to 140 parts of microcrystalline cellulose, 1.5 to 3.5 parts of disodium hydrogen phosphate, 2 to 5 parts of anhydrous sodium sulphite, 1 to 10 parts of crospovidone, 0.8 to 4.2 parts of lauryl sodium sulfate, 2 to 8 parts of povidone K30 and 1 to 3 parts of magnesium stearate.

The invention relates to a novel crystalline form of pregabalin drug for treating epilepsy and neuropathic pain and its preparation method. Compared to others pregabalin with agraphitic form and other forms, pregabalin with the novel crystalline form has good stability and is suitable for mass production. Pregabalin with the novel crystalline form uses Cu-Ka radiation and its X-ray powder diffraction has characteristic peak at 9.5(9.3), 12.3(7.2), 16.7(5.3), 18.4(4.8), 19.9(4.5) and 23.3(3.8) with the coordinate of 2-theta and interplanar spacing (d).

The invention discloses a crystal form F of ibrutinib. The crystal form F is characterized in that X-ray powder diffraction (X-RPD) which adopts Cu-Kalpha radiation and is represented with a 2theta angle has diffraction peaks in positions at angles of 3.7 degrees plus or minus 0.2 degrees, 6.7 degrees plus or minus 0.2 degrees, 13.2 degrees plus or minus 0.2 degrees, 16.1 degrees plus or minus 0.2 degrees, 19.1 degrees plus or minus 0.2 degrees, 20.0 degrees plus or minus 0.2 degrees, 23.8 degrees plus or minus 0.2 degrees and 24.6 degrees plus or minus 0.2 degrees. Related solvents in a preparation process of the crystal form F are cheap, the conditions are mild, the operation is simple, good controllability and reproducibility are realized, further, the prepared crystal form has great stability, the HPLC (high performance liquid chromatography) purity is higher than 99%, and the phenomenon of crystal transformation can be avoided; besides, the solubility is high, the dissolubility is good, and the bioavailability is high.

The invention relates to the field of medicinal chemistry, in particular to an Uloric crystal and a preparation method thereof. The Uloric crystal is characterized in that x-ray powder diffraction feature absorption peak (2theta) values have feature peaks at the parts of 6.70 degrees, 7.26 degrees, 9.40 degrees, 12.86 degrees, 13.42 degrees, 16.48 degrees, 19.70 degrees, 22.10 degrees, 23.16 degrees, 23.86 degrees, 25.02 degrees, 25.92 degrees, 26.74 degrees, 28.34 degrees and 40.48 degrees. An Uloric alpha crystal form of the invention has simple process operation and low cost. Only Uloric needs to be dissolved in a single solvent of ethylene glycol monomethyl ether so as to avoid solvation crystal habit, and the crystal form is stable and has good reproducibility. Moreover, the Uloric alpha crystal form has good solubility and better dissolution rate than A crystals in a solid preparation.

A hydroprocessing bulk catalyst is provided. A process to prepare hydroprocessing bulk catalysts is also provided. The hydroprocessing catalyst has the formula (R^p)_i(M^t)_a(L^u)_b(S^v)_d(C^w)_e(H^x)_f(O^y)_g(N^z)_h, wherein M is at least at least a “d” block element metal; L is also at least a “d” block element metal, but different from M; t, u, v, w, x, y, z representing the total charge for each of the components (M, L, S, C, H, O and N, respectively); R is optional and in one embodiment, R is a lanthanoid element metal; 0<=i<=1; pi+ta+ub+vd+we+xf+yg+zh=0; 0<b; 0<b/a=<5; 0.5(a+b)<=d<=5(a+b); 0<e<=11(a+b); 0<f<=7(a+b); 0<g<=5(a+b); 0<h<=2(a+b). The catalyst has an X-ray powder diffraction pattern with at least three diffractions peak located at 2-θ angles of greater than 25°. In one embodiment, the catalyst is prepared by forming at least a sulfided catalyst precursors from at least two “d” block element metals; and mixing the catalyst precursor with a hydrocarbon compound to form the hydroprocessing catalyst composition. In another embodiment, the catalyst is prepared by the thermal decomposition of an oil dispersible sulfur containing organic metal precursor upon contact with a hydrocarbon oil, generating a slurry catalyst. In yet another embodiment, the catalyst is prepared from an in-situ or ex-situ sulfidation of “d block element metal precursors in a solvent carrier.

The invention discloses zinc oxide hollow microspheres and a preparation method thereof. The invention relates to an inorganic nano material, and provides the zinc oxide hollow microspheres and the preparation method thereof. The zinc oxide hollow microspheres are made of wurtzite structural zinc oxide with powder diffraction standard joint committee number 36-1451, the diameters of the microspheres are 5 to 8 microns, and the thicknesses of the sphere walls are 0.5 to 1 micron. The preparation method comprises the following steps of: dissolving zinc nitrate hexahydrate and hexamethylene tetramine into water to obtain solution A, and adding sodium citrate into the solution A to obtain solution B; putting the solution B into a closed high pressure reactor, and putting the high pressure reactor into a drying oven to perform hydrothermal reaction; and after the hydrothermal reaction, cooling the reaction product to room temperature, opening the high pressure reactor, and filtering, washing and drying the sediment to obtain the zinc oxide hollow microspheres. The preparation method has the advantages of simplicity, convenience, low temperature, high yield and low sample dislocation density; and the zinc oxide hollow microspheres have broad application value in the fields of medicament release, photocatalysis, dye-sensitized solar cells and the like.

The invention provides a copolymer containing amorphous agomelatine. The detection of a sample of the copolymer by Differential Scanning Calorimetry (DSC) and X-ray powder diffraction shows that the sample has stable properties. The copolymer mainly comprises agomelatine raw material, carrier and solvent. The invention also provides a preparation method of the copolymer containing amorphous agomelatine, and the method has good reproducibility. The invention further provides a pharmaceutical composition containing the copolymer containing amorphous agomelatine and an application of the copolymer containing amorphous agomelatine in preparing medicines for treating depression.

The present invention relates to new organic-inorganic hybrid silicates and metal-silicates called ECS, characterized by an X-ray powder diffraction pattern with reflections exclusively at angular values higher than 4.0° of 2θ, preferably at angular values higher than 4.7°, and an ordered structure containing structural units having formula (a) wherein R is an organic group: Formula (a) and possibly containing one or more elements T selected from groups III B, IV B, V B and transition metals, with a Si/(Si +T) molar ratio in said structure higher than 0.3 and lower than or equal to 1, wherein Si is the silicon contained in the structural unit (a). A process is also described, starting from disilanes, for the preparation of these materials, which does not include the use of templates or surfactants. These materials can be used as molecular sieves, adsorbents, in the field of catalysis, in the field of electronics, in the field of sensors, in the field of nanotechnologies.

The invention discloses a new crystal form of S-oxiracetam and a preparation method thereof. The new crystal form is characterized in that: characteristic absorption peaks exist when a reflected angle 2 theta is about 12.1, 17.5, 19.7, 21.4, 24.7, 29.3 and 32.0 in an X-ray powder diffraction pattern.